According to the researchers of this new study, the biomarker may have potential for use with clinical scores in treatment decisions or in clinical trials that focus on hidradenitis suppurativa (HS).
New research is signaling that a simple and cost-effective biomarker may be used to monitor the severity of hidradenitis suppurativa (HS).
The retrospective study of patients with the condition showed that pan-immune-inflammation value (PIV), across a variety of biomarkers, had the strongest indications for HS severity. According to the researchers, whose findings appear in Journal of the European Academy of Dermatology and Venereology, the biomarker may be able to be used with clinical scores in treatment decisions or in clinical trials.
“In routine clinic evaluation of HS disease, severity based only on clinical features can be a challenge (eg, distinguishing Hurley II and Hurley III),” explained the researchers. “Hence, diagnostic and monitoring biomarkers for HS are needed. Data regarding the association of serum markers of inflammation with HS disease severity have recently been reported by our research group.”
Across the 142 patients with HS and 35 sex- and age-matched controls, the researchers saw a significant positive correlation between modified HS score (mHSS) and PIV (r = 0.32; P < .0001), in addition to neutrophil to lymphocyte ratio (NLR) (r = 0.17; P = .0415), monocyte to lymphocyte ratio (MLR) (r = 0.23; P = .0052), and systemic immune-inflammation index (SII) (r = 0.19; P = 0.0222). They also found that the platelet to neutrophil ratio (PNR) had a negative correlation with mHSS (r = –0.21; P = .0124).
Compared with the controls, patients with HS had significantly higher PIV and SII, although PIV—a combination of neutrophil, platelet, and monocyte counts—was the only biomarker significantly associated with severity based on the Youden index, with an index of 0.56.
PIV also showed an area under the curve (AUC) of 0.79 (95% CI, 0.71-0.85; P < .0001), with a sensitivity of 59.3 and a specificity of 96.5.
The platelet to lymphocyte ratio (PLR), MLR, and PNR were all significantly lower in these patients compared with the controls. Previous research has connected NLR and PLR with the severity of skin inflammatory diseases, although this correlation has not previously been studied in HS specifically.
“On the basis of our data, PLR does not appear to be a suitable biomarker for disease activity or severity,” described the researchers. “By contrast, NLR, MLR, PNR, SII, and PIV positively or negatively correlated with HS severity. However, the AUC values for Hurley stage and [Severity Assessment of Hidradenitis Suppurativa score] were relatively poor for NLR, MLR, PNR, and SII.”
Reference
Gambichler T, Hessam S, Cramer P, Rached NA, Bechara G. Complete blood collection-based systemic inflammation biomarkers for patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. Published online April 24, 2022. doi:10.1111/jdv.18175
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen